Concentra Group Holdings Parent, Inc. (CON)

S&P Global Ratings has upgraded Concentra Group Holdings Parent Inc. (NYSE: CON) to BB from BB-, citing strong operating performance and significantly lower leverage. This upgrade follows Concentra's separation from Select Medical, with adjusted leverage falling below 3.5x in Q2, ahead of forecasts. The company's stable outlook reflects expectations of maintaining leverage below 3.5x, driven by robust free operating cash flow and a dominant market share in occupational health.

Concentra Group Holdings Parent, Inc. completed a $34.65 million share buyback from its Board Chairman Robert A. Ortenzio and affiliated entities. The company repurchased 1,000,000 common stock shares at $34.65 per share, representing a 1% discount to the closing price on August 21, 2026. This privately negotiated transaction, approved by the Audit and Compliance Committee, was financed using the company's available cash and was part of an existing buyback program.

Concentra Group Holdings Parent, Inc. (CON) purchased 1,000,000 shares of common stock at $34.65 per share from director Robert A. Ortenzio and associated family trusts. Ortenzio directly disposed of 770,000 shares and indirectly disposed of 230,000 shares through family trusts. Following the transaction, he directly holds 4,763,794 shares, with additional indirect holdings.

Concentra Group Holdings Parent, Inc. announced the appointment of Jill Rosenthal, MD, MPH, as its new chief medical officer, effective January 1, 2027, succeeding Dr. John Anderson. Dr. Rosenthal's experience in clinical leadership and occupational medicine is expected to support Concentra's clinical execution, though the immediate focus remains on debt management and EBITDA margins. This leadership change, alongside a new CEO succession plan, is anticipated to influence the company's clinic expansion and integrated workforce health offerings.

Concentra Group Holdings Parent, Inc. (CON) has entered into a Stock Repurchase Agreement to buy back 1,000,000 shares of its common stock from Robert A. Ortenzio and related family trusts for a total of $34,650,000, at a price of $34.65 per share. Following this transaction, Ortenzio's beneficial ownership in Concentra will be 6,748,222 shares, representing approximately 5.3% of the outstanding shares. The agreement was made on August 21, 2026, and details the voting and dispositive powers over these shares.